Please login to the form below

Not currently logged in
Email:
Password:

acalabrutinib

This page shows the latest acalabrutinib news and features for those working in and with pharma, biotech and healthcare.

AZ expects return to growth this year after 2017 decline

AZ expects return to growth this year after 2017 decline

AZ brought five new medicines to market in 2017 - including new cancer medicines Imfinzi (durvalumab) and Calquence (acalabrutinib) as well as Fasenra (benralizumab) for asthma - and added new indications for Lynparza

Latest news

  • AZ CEO says company’s renaissance is on track AZ CEO says company’s renaissance is on track

    Soriot also pointed to a turnaround in AZ’s R&D pipeline, pointing to approvals of four new medicines this year - including BTK inhibitor Calquence (acalabrutinib) - and “positive developments”for Tagrisso

  • Sanofi licences Principia MS drug in $805m deal Sanofi licences Principia MS drug in $805m deal

    BTK is best known as the target for Johnson/AbbVie's big-selling blood cancer therapy Imbruvica (ibrutinib) and AstraZeneca’s recently-approved rival Calquence (acalabrutinib).

  • AZ gets early FDA green light for Imbruvica challenger AZ gets early FDA green light for Imbruvica challenger

    AstraZeneca claimed its first regulatory approval for BTK inhibitor acalabrutinib in the US, with the FDA clearing the drug for second-line therapy for adults with mantel cell lymphoma. ... The FDA has previously awarded acalabrutinib breakthrough and

  • Clock starts ticking on FDA review of AZ's acalabrutinib Clock starts ticking on FDA review of AZ's acalabrutinib

    Clock starts ticking on FDA review of AZ's acalabrutinib. If approved, the BTK inhibitor could achieve annual peak sales of $5bn. ... The FDA has started its review of AstraZeneca's BTK inhibitor acalabrutinib, shortly after granting the drug a

  • Strong Tagrisso soothes AZ as US sales plummet Strong Tagrisso soothes AZ as US sales plummet

    Meanwhile in its targeted oncology portfolio AZ is also expecting to file BTK inhibitor acalabrutinib for B-cell malignancies later this year, with MEK inhibitor selumetinib for thyroid cancer and  moxetumomab

More from news
Approximately 1 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...
Unique forum will unite NHS and industry to drive innovation
HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at Wilmington Healthcare...

Infographics